# Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

> **NCT02119247** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 44 (actual)

## Conditions studied

- COPD

## Interventions

- **DEVICE:** CHF 6001 dry powder for inhalation via NEXThaler®
- **DEVICE:** CHF 6001 DPI capsules for inhalation via Aerolizer

## Key facts

- **NCT ID:** NCT02119247
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02119247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02119247, "Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02119247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*